Dr. Anderson on the GRIFFIN Study With D-RVd in Multiple Myeloma
April 18th 2020Larry Anderson, MD, PhD, discusses the phase II GRIFFIN trial examining the addition of daratumumab (Darzalex) to lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (D-RVd) in patients with multiple myeloma.
Long-Term Follow-Up Validates Noninferiority Between Radiation Regimens in Prostate Cancer
March 25th 2020Moderate hypofractionated intensity-modulated radiation therapy did not show biochemical and/or clinical disease failure rate superiority compared with conventionally fractioned IMRT for men with intermediate- and high-risk prostate adenocarcinoma.